연구동향 분석

(The) Comprehensive Analysis of Genomic, Transcriptomic, and Pathologic Changes after Acquisition of Resistance to Immune Checkpoint Inhibitors

유신혜 2020년

논문상세정보
인용/피인용
' (The) Comprehensive Analysis of Genomic, Transcriptomic, and Pathologic Changes after Acquisition of Resistance to Immune Checkpoint Inhibitors' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 의료과학 약
  • Programmed death ligand 1
  • Immune checkpoint inhibitor
  • Mechanism
  • Next generation sequencing
  • acquired resistance
  • immunohistochemistry
  • pik3ca
  • 기전
  • 면역관문억제제
  • 면역화학염색
  • 차세대 염기 서열 분석
  • 획득내성
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
4,410 0

0.0%

' (The) Comprehensive Analysis of Genomic, Transcriptomic, and Pathologic Changes after Acquisition of Resistance to Immune Checkpoint Inhibitors' 의 참고문헌

  • beta-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma
    9 ( 8 ) :1124-41 . [2019]
  • Yamaguchi H. Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer
    [2019]
  • Y. Pretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors : A meta-analysis
    9 ( 10 ) :1220-30 . [2018]
  • WNT/beta-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers
    25 ( 10 ) :3074-83 [2019]
  • Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement
    3 ( 24 ) . [2018]
  • Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy
    130:4316-31 [2019]
  • Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors : A Review of Current Evidence
    25 ( 1 ) : e147-e59 . [2020]
  • Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors : A Systematic Review and Meta-Analysis
    11 ( 11 ) . [2019]
  • Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
    167 ( 6 ) :1540-54 e12 . [2016]
  • The role of PD-L1 expression as a predictive biomarker : an analysis of all US Food and Drug Administration ( FDA ) approvals of immune checkpoint inhibitors
    7 ( 1 ) :278 . [2019]
  • The immune response-related mutational signatures and driver genes in non-small-cell lung cancer
    110 ( 8 ) :2348-56 . [2019]
  • The cBio Cancer Genomics Portal : An Open Platform for Exploring Multidimensional Cancer Genomics Data
    2 ( 5 ) :401-4 . [2012]
  • The blockade of immune checkpoints in cancer immunotherapy
    12 ( 4 ) :252-64 . [2012]
  • The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck ( HNSCC )
    7 ( 1 ) :184 . [2019]
  • The Genome Analysis Toolkit : a MapReduce framework for analyzing next-generation DNA sequencing data
    20 ( 9 ) :1297-303 . [2010]
  • The Different Mechanisms of Cancer Drug Resistance : A Brief Review
    7 ( 3 ) :339- 48 . [2017]
  • The APOBEC3 genes and their role in cancer : insights from human papillomavirus
    [2019]
  • Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution
    9 ( 1 ) :32 . [2018]
  • Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPVtumors
    5 ( 5 ) :49 . [2013]
  • T-Cell Transfer Th erapy Targeting Mutant KRAS in Cancer
    375 ( 23 ) :2255-62 . [2016]
  • Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
    4 ( 1 ) :44-57 . [2009]
  • Swanton C. DeconstructSigs : delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution
    0.729861111111111 [2016]
  • Stratton MR. Deciphering signatures of mutational processes operative in human cancer
    3 ( 1 ) :246-59 . [2013]
  • Signatures of mutational processes in humanCancer
    500 ( 7463 ) :415-21 . [2013]
  • Serum lactate dehydrogenase as an early marker for outcome in patients treated with antiPD-1 therapy in metastatic melanoma .
    114 ( 3 ) :256-61 . [2016]
  • Secondary resistance to immunotherapy associated with beta-catenin pathway activation or PTEN loss in metastatic melanoma .
    7 ( 1 ) :295 . [2019]
  • STAR : ultrafast universal RNA-seq aligner
    29 ( 1 ) :15-21 . [2013]
  • Robust enumeration ofCell subsets from tissue expression profiles
    12 ( 5 ) :453-7 . [2015]
  • Review of Indications of FDA-Approved ImmuneCheckpoint Inhibitors per NCCN Guidelines with the Level of Evidence
    12 ( 3 ) . [2020]
  • Resistance to Targeted Therapies : Refining Anticancer Therapy in the Era of Molecular Oncology
    15 ( 24 ) :7471-8 . [2009]
  • Remarkable Alteration of PD-L1 Expression after ImmuneCheckpoint Therapy in Patients with Non-Small-Cell LungCancer : Two AutopsyCase Reports
    20 ( 10 ) . [2019]
  • RSEM : accurate transcript quantification from RNA-Seq data with or without a reference genome
    0.724305556 [2011]
  • Prognostic impact of PD-1 and its ligands in renalCellCarcinoma
    34 ( 6 ) :99 . [2017]
  • Primary and Acquired Resistance to ImmuneCheckpoint Inhibitors in Metastatic Melanoma
    24 ( 6 ) :1260- 70 [2018]
  • Primary , Adaptive , and Acquired Resistance toCancer Immunotherapy
    168 ( 4 ) :707-23 . [2017]
  • Prevalence and mutational determinants of high tumor mutation burden in breastCancer .
    31 ( 3 ) :387-94 . [2020]
  • Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lungCancer
    106:1-7 [2017]
  • PositiveConversion of PD-L1 Expression After Treatments withChemotherapy and Nivolumab
    37 ( 10 ) :5713-7 . [2017]
  • PI3Kgamma is a molecular switch thatControls immune suppression
    539 ( 7629 ) :437-42 . [2016]
  • PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy
    24 ( 1 ) :41-6 . [2018]
  • PD-1 Blockade in Tumors with Mismatch-Repair Deficiency .
    373 ( 20 ) :1979 . [2015]
  • Optimal cutoff for neutrophil-to-lymphocyte ratio : Fact or Fantasy ? A prospective cohort study in metastatic cancer patients
    13 ( 4 ) : e0195042 . [2018]
  • Oncogenic Signaling Pathways in The Cancer Genome Atlas
    173 ( 2 ) :321-37 e10 [2018]
  • OncoKB : A Precision Oncology Knowledge Base
    [2017]
  • Odunsi K. Compensatory upregulation of PD-1 , LAG-3 , and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer
    6 ( 1 ) : e1249561 . [2017]
  • Novel patterns of response under immunotherapy
    30 ( 3 ) :385-96 . [2019]
  • Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden .
    378 ( 22 ) :2093-104 . [2018]
  • New response evaluationCriteria in solid tumours : revised RECIST guideline ( version 1.1 )
    45 ( 2 ) :228-47 . [2009]
  • Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma .
    375 ( 9 ) :819-29 . [2016]
  • Mutational processes molding the genomes of 21 breast cancers
    149 ( 5 ) :979- 93 . [2012]
  • Molecular Mechanism of beta-Catenin Signaling Pathway Inactivation in ETV1-Positive Prostate Cancers
    2 ( 3 ) :208-16 . [2015]
  • Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
    357 ( 6349 ) :409-13 . [2017]
  • Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity
    523 ( 7559 ) :231-5 . [2015]
  • Mechanisms of resistance to immune checkpoint inhibitors
    118 ( 1 ) :9-16 [2018]
  • Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
    13 ( 1 ) :84-8 . [2007]
  • Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
    6 ( 2 ) :202-16 . [2016]
  • Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma .
    46 ( 2 ) :197-204 . [2017]
  • Loss of IFN-gamma Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
    167 ( 2 ) :397-404 e9 [2016]
  • Li T. Translational Biomarkers and Rationale Strategies to Overcome Resistance to Immune Checkpoint Inhibitors in Solid Tumors
    [2020]
  • Lemaire V. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy
    29 ( 1 ) :71-83 . [2018]
  • Le Tourneau C. Patterns of Response and Progression to Immunotherapy
    38:169-78 [2018]
  • Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy
    14 ( 4 ) :847-56 . [2015]
  • Kitamura T. Macrophage targeting : opening new possibilities for cancer immunotherapy
    155 ( 3 ) :285-93 . [2018]
  • Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
    6 ( 269 ) : pl1 . [2013]
  • Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer
    8 ( 5 ) : e1581556 . [2019]
  • Inferring tumour purity and stromal and immune cell admixture from expression data
    1.980555556 [2013]
  • Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC
    9 ( 2 ) :144-53 . [2014]
  • Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
    7 ( 12 ) :1420-35 [2017]
  • Immunotherapy in genitourinary malignancies .
    26 ( 6 ) :501-7 . [2016]
  • Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell-Mediated Inflammation and Immunosuppression
    7 ( 9 ) :1497-510 . [2019]
  • Immune Checkpoint Blockade across the Cancer Care Continuum
    48 ( 6 ) :1077-80 . [2018]
  • IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade
    127 ( 8 ) :2930-40 [2017]
  • Hu-Lieskovan S. Mechanisms of Resistance to Immune Checkpoint Blockade : Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients ?
    39:147-64 [2019]
  • HisgAtlas 1.0 : a human immunosuppression gene database
    [2017]
  • Hakonarson H. ANNOVAR : functional annotation of genetic variants from high-throughput sequencing data .
    38 ( 16 ) : e164 . [2010]
  • Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity .
    160 ( 1- 2 ) :48-61 . [2015]
  • Goto S. KEGG : kyoto encyclopedia of genes and genomes
    28 ( 1 ) :27-30 . [2000]
  • Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response
    9 ( 1 ) . [2020]
  • Gene set enrichment analysis : A knowledge-based approach for interpreting genome-wide expression profiles .
    102 ( 43 ) :15545-50 . [2005]
  • Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers
    3 ( 7 ) :761-9 . [2013]
  • Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors
    46 ( 4 ) :577-86 . [2017]
  • Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
    36 ( 10 ) :2638-78 . [2019]
  • Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
    7 ( 3 ) :264-76 . [2017]
  • Enhanced copy number variants detection from whole-exome sequencing data using EXCAVATOR2
    44 ( 20 ) : e154 . [2016]
  • Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
    33 ( 4 ) :581-98 . [2018]
  • Elkord E. Treg-mediated acquired resistance to immune checkpoint inhibitors
    457:168-79 [2019]
  • Elkord E. Immune checkpoint inhibitors : recent progress and potential biomarkers
    50 ( 12 ) :1-11 [2018]
  • Elkord E. Acquired resistance to cancer immunotherapy : Role of tumormediated immunosuppression
    [2019]
  • Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform
    26 ( 5 ) :589-95 . [2010]
  • Drug Resistance in Cancer : An Overview
    6 ( 3 ) :1769-92 . [2014]
  • Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma : Implications for PD-1 Pathway Blockade .
    21 ( 17 ) :3969- 76 . [2015]
  • De-novo and acquired resistance to immune checkpoint targeting
    18 ( 12 ) : e731-e41 . [2017]
  • Costantini F. Wnt/betacatenin/Tcf signaling induces the transcription of Axin2 , a negative regulator of the signaling pathway
    22 ( 4 ) :1172-83 . [2002]
  • Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non-Small-Cell Lung Cancer
    19 ( 5 ) :426-34 e1 [2018]
  • Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
    76 ( 2 ) :227-38 . [2016]
  • Comparative Analysis of Durable Responses on Immune Checkpoint Inhibitors Versus Other Systemic Therapies : A Pooled Analysis of Phase III Trials
    3:1-10 [2019]
  • Clonal Deletion of Tumor-Specific T Cells by Interferon-gamma Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade
    50 ( 2 ) :477-92 e8 [2019]
  • Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non-Small Cell Lung Cancer
    13 ( 6 ) :831-9 . [2018]
  • ClinVar : public archive of interpretations of clinically relevant variants .
    44 ( D1 ) : D862-8 . [2016]
  • Cellular Senescence : Defining a Path Forward
    179 ( 4 ) :813-27 . [2019]
  • Cavazzoni A. PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition
    11 ( 9 ) . [2019]
  • Casaluce F. Frontline immunotherapy for NSCLC : alone or not alone ?
    15 ( 10 ) :593-4 [2018]
  • Cancer immunology . Mutational landscape determines sensitivity to PD-1 blockade in nonsmall cell lung cancer .
    348 ( 6230 ) :124-8 . [2015]
  • COSMIC : the Catalogue Of Somatic Mutations In Cancer
    47 ( D1 ) : D941-D7 . [2019]
  • CNVkit : Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing
    12 ( 4 ) : e1004873 . [2016]
  • Biomarkers of immunotherapy in urothelial and renal cell carcinoma : PD-L1 , tumor mutational burden , and beyond
    6 ( 1 ) :4 . [2018]
  • Bernards R. Drug resistance to targeted therapies : deja vu all over again
    8 ( 6 ) :1067-83 . [2014]
  • Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumabtreated metastatic melanoma patients .
    112 ( 12 ) :1904-10 . [2015]
  • Baseline neutrophil-to-lymphocyte ratio ( NLR ) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
    6 ( 1 ) :74 . [2018]
  • Bar-Sela G. The role of tumorinfiltrating lymphocytes ( TILs ) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma .
    35 ( 3 ) :25 . [2018]
  • Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3Kdelta/gamma
    77 ( 10 ) :2607-19 . [2017]
  • Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
    6 ( 8 ) :827-37 [2016]
  • Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden .
    9 ( 1 ) :34 . [2017]
  • An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers
    45 ( 9 ) :970-6 . [2013]
  • Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
    7:10501 [2016]
  • Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer
    6 ( 1 ) : e1261779 . [2017]
  • Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA
    9 ( 1 ) :3868 . [2018]
  • Acquired Resistance to Immune Checkpoint Inhibitors
    37 ( 4 ) :443-55 . [2020]
  • APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer
    37 ( 29 ) :3924-36 . [2018]
  • APOBEC-related mutagenesis and neo-peptide hydrophobicity : implications for response to immunotherapy
    8 ( 3 ) :1550341 . [2019]
  • APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirusdriven tumor development
    7 ( 6 ) :1833-41 . [2014]
  • A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations .
    31 ( 6 ) :820-32 e3 . [2017]
  • 3 ) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer
    28 ( 2 ) :306-12 . [2009]